Skip to content
Screener

Sarepta Therapeutics, Inc. SRPT Business Segments — Investment Income Interest

Similar metrics at other companies

Mannkind logo
MNKDAll Other Segments — Investment Income Interest
$1.02M-44.2%
Rush Enterprises logo
RUSHAAll Other Segments — Investment Income Interest
$0
Village Farms International, Inc. logo
VFFAll Other Segments — Investment Income Interest
$44K+4,300%
Apogee Therapeutics, Inc. logo
APGEReportable Segment Aggregation Before Other Operating — Investment Income Interest
$8.74M+11.5%
Phathom Pharmaceuticals, Inc. logo
PHATReportable Segment Aggregation Before Other Operating — Investment Income Interest
$1.51M-78.6%
Aeva Technologies logo
AEVAReportable Segment Aggregation Before Other Operating — Investment Income Interest
$877K-12.9%

Other financials

Income statement

See full
Revenue$401.3M-34.3%
Operating income$13.3M-88.5%
Net income-$4.9M-102%
EPS (diluted)-$0.05-103%

Balance sheet

See full
Cash & equivalents$571.1M+11.9%
Total debt$198.2M-7.6%
Total equity$1.5B+8.8%
Total assets$3.2B-13.4%

Cash flow

See full
Operating cash flow-$202.7M+65.3%
CapEx$555.0K-98.3%
Free cash flow-$204.8M+67.3%

Valuation

See full
Market cap$1.77B+10.9%
Enterprise value$1.4B+7.5%
P/S0.9×

Profitability

See full
Operating margin-50.8%-1.6pp
Net margin-6.9%
FCF margin-28.7%-9.2pp

Returns & leverage

See full
Return on equity-9.3%+2,662pp
Debt / equity0.1×0.0×
Current ratio4.4×+1.5×

Where this comes from

Reported directly by Sarepta Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:InvestmentIncomeInterest.

The source filing: Sarepta Therapeutics, Inc.’s 10-Q, filed August 5, 2026.

Filed
Aug 5, 2026, 4:01 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-335003
Line itemFor the Three Months Ended June 30, 2026For the Three Months Ended June 30, 2025For the Six Months Ended June 30, 2026For the Six Months Ended June 30, 2025
Other segment items (3)(709)(1,314)(2,515)(3,223)
Loss (gain) on strategic investments448(36,721)2,16054,007
Interest expense21,5085,22843,2219,731
Interest income(6,207)(5,254)(12,567)(15,444)
Income tax expense (benefit)3,141(43,254)15,35620,736
Depreciation and amortization expense10,40910,84021,00320,818
Stock-based compensation expense24,47237,02553,87178,453
Litigation contingency charge39,00039,000

Item 1. Financial Statements

FAQ

What is Sarepta Therapeutics, Inc.'s business segments — investment income interest?
Sarepta Therapeutics, Inc. (SRPT) reported business segments — investment income interest of -$6.21M in Q2 2026.
How has Sarepta Therapeutics, Inc.'s business segments — investment income interest changed year-over-year?
Sarepta Therapeutics, Inc.'s business segments — investment income interest decreased by 18.1% year-over-year, from -$5.25M to -$6.21M.
What does business segments — investment income interest mean?
Income generated from interest-bearing financial instruments or cash equivalents held by the segment. This reflects the segment's ability to earn returns on its idle cash or short-term investments. It serves as a non-operating contributor to the segment's overall financial health.

Ask your AI about Sarepta Therapeutics, Inc.'s business segments — investment income interest.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude